Abstract
To date, the general assumption was that most mutations interested protein-coding genes only. Thus, only few illustrations have mentioned here that mutations may occur in non-protein coding genes such as microRNAs (miRNAs). We thus report progress in delineating their contribution as phenotypic modulators, genetic switches and fine-tuners of gene expression. We reasoned that browsing their contribution to genetic disease may provide a framework for understanding the proper requirements to devise miRNA-based therapy strategies, in particular the relief of an appropriate dosage. Gain and loss of function of miRNA enforce the need to respectively antagonize or supply the miRNAs. We further categorized human disease according to the different ways in which the miRNA was altered arising either de novo, or inherited whether as a mendelian or as an epistatic trait, uncovering its role in epigenetics. We discuss how improving our knowledge on the contribution of miRNAs to genetic disease may be beneficial to devise appropriate gene therapy strategies.
Keywords: anti-miRs, disease, dosage, genetics, genotype, microRNA, mimics.
Current Gene Therapy
Title:MicroRNAs in Genetic Disease: Rethinking the Dosage
Volume: 12 Issue: 4
Author(s): Alexandra Henrion-Caude, Muriel Girard and Jeanne Amiel
Affiliation:
Keywords: anti-miRs, disease, dosage, genetics, genotype, microRNA, mimics.
Abstract: To date, the general assumption was that most mutations interested protein-coding genes only. Thus, only few illustrations have mentioned here that mutations may occur in non-protein coding genes such as microRNAs (miRNAs). We thus report progress in delineating their contribution as phenotypic modulators, genetic switches and fine-tuners of gene expression. We reasoned that browsing their contribution to genetic disease may provide a framework for understanding the proper requirements to devise miRNA-based therapy strategies, in particular the relief of an appropriate dosage. Gain and loss of function of miRNA enforce the need to respectively antagonize or supply the miRNAs. We further categorized human disease according to the different ways in which the miRNA was altered arising either de novo, or inherited whether as a mendelian or as an epistatic trait, uncovering its role in epigenetics. We discuss how improving our knowledge on the contribution of miRNAs to genetic disease may be beneficial to devise appropriate gene therapy strategies.
Export Options
About this article
Cite this article as:
Henrion-Caude Alexandra, Girard Muriel and Amiel Jeanne, MicroRNAs in Genetic Disease: Rethinking the Dosage, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083602
DOI https://dx.doi.org/10.2174/156652312802083602 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA Expression and Function of PPARs in Cancer Stem Cells
Current Stem Cell Research & Therapy Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Platelet Activation, Inflammatory Mediators and Hypercholesterolemia
Current Vascular Pharmacology Large A-V Fistula: Pathophysiological Consequences and Therapeutic Perspectives
Current Vascular Pharmacology Transient Receptor Potential Channels in Human Platelets: Expression and Functional Role
Current Molecular Medicine Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis The Effect of Non-Thermal Microwave-Treated Physiological Solution on Isolated Heart Muscle of Snail
Current Chemical Biology Role of Beta2 Agonists in Respiratory Medicine with Particular Attention to Novel Patents and Effects on Endocrine System and Immune Response
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Analysis of QTc Interval during Levofloxacin Prescription in Cardiac Patients with Pneumonia
Current Drug Safety Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Synthesis of 1,2,4-triazole Derivatives: Binding Properties on Endothelin Receptors
Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets